Skip to main content

Table 1 Characteristics and diagnoses of patients

From: Can the clinical sign “head-turning sign” and simple questions in “Neucop-Q” predict amyloid β pathology?

 

n

Male (%)

Age (years)

education(y)

CDRsum

MMSE

ADAS

FAQ

ApoE4+(%)

total

155

77(49.7)

69.5 ± 10.3

14.6 ± 2.0

1.75 ± 3.00

25.5 ± 5.4

10.3 ± 10.3

2.84 ± 4.57

36.8

CN

47

26(55.3)

70.2 ± 7.7

15.0 ± 2.2

0.01 ± 0.07

29.0 ± 1.1

4.3 ± 2.3

0.43 ± 1.04

31.9

MCI due to AD

19

8(42.1)

72.5 ± 10.0

14.2 ± 1.9

0.63 ± 1.10*

27.2 ± 2.4*

6.4 ± 4.4*

1.33 ± 3.59*

52.6

MCI due to non AD

17

12(70.59)

73.2 ± 9.2

14.9 ± 2.0

0.85 ± 0.68*

27.2 ± 1.9*

7.2 ± 3.7*

0.71 ± 1.05*

29.4

AD

31

13(41.9)

73.7 ± 9.1*

14.3 ± 1.8

3.87 ± 3.47*

18.9 ± 6.2*

20.8 ± 10.3*

6.55 ± 5.58*

54.8†

non-AD dementia

33

16(48.5)

62.2 ± 11.7*

14.7 ± 1.9

3.36 ± 4.25*

24.2 ± 5.4*

13.7 ± 14.6*

5.00 ± 5.58*

24.2

psychiatric disorders

8

3(30.0)

64.6 ± 10.8

14.4 ± 2.3

0.13 ± 0.23*

28.1 ± 1.9

4.04 ± 1.4

0.25 ± 0.71

0

  1. Abbreviations: MMSE, Mini-Mental State Examination; CDR-SB, Clinical Dementia Rating Scale-Sum of Boxes; ADAS, Alzheimer’s Disease Assessment Scale; ApoE, apolipoprotein E; CN: cognitive normal, AD: Alzheimer’s disease, MCI: mild cognitive impairment, A/T: amyloidβ/tau pathology
  2. Notes: Data are presented as mean (SD or %). *; Differences from CN were assessed using the Wilcoxon test. p < 0.05, ; Differences between each two groups were assessed using χ2 test